Trial · NCT05888233
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Normalized peak early diastolic filling rate (E) | 8 weeks | Change from baseline in left ventricular diastolic function index: Normalized peak early diastolic filling rate (E) after 8-weeks of treatment with Allopurinol. (Range 1.5 - 3.0 end-diastolic velocity (EDV)/second) |
| Primary | Six minute walk test | 8 weeks | Change in exercise capacity by six minute walk test after 8-weeks of Allopurinol. Timed activity for distance walked (Distance range approximately 400-800 meters (m); Further distance = better outcome) |
| Primary | Self Reported health survey for Heart Failure | 8 weeks | Change in self reported quality of life measures using Kansas City Heart Failure Questionnaire (KCCQ-12) after 8-weeks of Allopurinol. Scale (Minimum - 0 ; Maximum - 100; High score = worse outcome) |
| Primary | Self reported Health Survey | 8 weeks | Change in self reported quality of life measures using the Quality of Life Medical Outcomes Study Questionnaire (SF 36 QOL) after 8-weeks of Allopurinol. Scale (Minimum - 0; Maximum - 100; High score = worse outcome) |
| Primary | Left ventricular end-diastolic volume index | 8 weeks | Change from baseline in left ventricular diastolic function index: left ventricular end diastolic volume normalized to body surface area after 8-weeks of treatment with Allopurinol. (Range 40 - 100 milliliters per square meter (mL/m2) |
| Primary | Left ventricular (LV) end-diastolic mass index | 8 weeks | Change from baseline in left ventricular diastolic function index: LV end-diastolic mass indexed to body surface area after 8-weeks of treatment with Allopurinol. (Range: 40-100 grams/square meter (m2) |
| Primary | Left ventricular (LV) end-diastolic fractional shortening | 8 weeks | Change from baseline in left ventricular diastolic function index: LV end-diastolic fractional shortening after 8-weeks of treatment with Allopurinol. (Range: 15-80%) |
| Primary | Left ventricular (LV) end-diastolic mid-wall radius to wall thickness ratio | 8 weeks | Change from baseline in left ventricular diastolic function index: LV end-diastolic mid-wall radius to wall thickness ratio. Ratio (no units; Range: 1.5-4.0). |
| Primary | Normalized peak late diastolic filling rate (A), EDV/s | 8 weeks | Change from baseline in left ventricular diastolic function index: Normalized peak late diastolic filling rate (A) after 8-weeks of treatment with Allopurinol. (Range 1.3 - 4.5 end-diastolic velocity (EDV)/second) |
| Secondary | Systolic Blood Pressure | 8 weeks | Change in systolic blood pressure after 8 weeks of Allopurinol. Range: 120-200 millimeters of mercury (mmHg) |
| Secondary | Xanthine Oxidase | 8 weeks | Change in systemic levels of xanthine oxidase (range - Xanthine oxidase activity, U/mg protein - Range 0 - 0.1) |
| Secondary | mitochondrial DNA damage-associated molecular patterns | 8 weeks | Change in systemic levels of mitochondrial DNA damage-associated molecular patterns (range 0-5000 copies/uL) |
| Secondary | Brain Natriuretic Peptide | 8 weeks | Change in systemic levels of brain natriuretic peptide (BNP) after 8 weeks of Allopurinol (Scale 0 to \> 100 pgmL; Minimum 0; Maximum \>100). |
| Secondary | Diastolic Blood Pressure | 8 weeks | Change in diastolic blood pressure after 8 weeks of Allopurinol. Range: 70-110 millimeters of mercury (mmHg) |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05888233/registered